X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its ...

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

X4 Pharmaceuticals (XFOR) announced a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat ...

BOSTON—X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a biotech company with a market capitalization of $84 million, saw its Chief ...

X4 Pharmaceuticals, Inc.’s XFOR share price has surged by 52.59%, which has investors questioning if this is right time to ...

在2025年寒冬的试驾日，我先后体验了宝马X4与X5两款车型，深刻感受到这两款豪华SUV截然不同的性格。作为轿跑SUV与经典旗舰的代表，它们用差异化的产品力诠释了宝马对细分市场的精准把控。 座舱体验：个性空间与行政豪华的博弈 ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...